The device maker's planned acquisition of Covidien will make it a force to be reckoned with.
Our picks from the ideas of some of the best investment minds around.
Market volatility has shaped the performance of many top managers this year.
Plus, Pfizer stubs a toe, DeVry draws undergrads, and more.
M&A activity contributes to surge.
A roundup of investment news.